Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

Press release content from PR Newswire. The AP news staff was not involved in its creation.
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration
December 18, 2020 GMT
TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ -- Teijin Pharma Limited (“Teijin Pharma”), the core company of the Teijin Group ’s healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, jointly announced that they have entered into a strategic collaboration agreement for joint research and development of the innovative drugs in the target fields of oncology and inflammatory diseases.
Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma, and share the research outcomes in both Japan and China. Also, the two companies will share a global development license when the compound enters the development stage and consider the joint development and launch of new drugs in Japan, China, and rest of the world.

Related Keywords

China , Japan , Tokyo , Nanjing , Jiangsu , Japanese , Chinese , Yasushi Honma , Hidehiro Ando , Transthera Biosciences , Ichiro Watanabe , Teijin Pharma , Keiji Kawamoto , Frank Wu , Prnewswire Teijin Pharma Limited , Senior Advisor Of External Alliance Transthera , Transthera Biosciences Co , Human Solutions , Teijin Group , Komong Associates , Pharma Limited , Senior Advisor , External Alliance , Thera Biosciences , Japan Cross Border , சீனா , ஜப்பான் , டோக்கியோ , நான்ஜிங் , ஜப்பானிய , சீன , கேஜி காவமோடோ , வெளிப்படையான வு , மனிதன் தீர்வுகள் , பார்மா வரையறுக்கப்பட்டவை , வெளிப்புறம் கூட்டணி , தேரா உயிர் அறிவியல் , ஜப்பான் குறுக்கு எல்லை ,